We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$1.39B
Cap. Flow %
-6.39%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Communication Services 8.41%
3 Technology 5.7%
4 Financials 3.99%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
151
Novavax
NVAX
$1.47B
– –
-22,000
Closed -$179K
OCUL icon
152
Ocular Therapeutix
OCUL
$2.43B
– –
-18,000
Closed -$152K
OMER icon
153
Omeros
OMER
$1.39B
– –
-23,000
Closed -$243K
OSCR icon
154
Oscar Health
OSCR
$9.89B
– –
-11,000
Closed -$126K
PCVX icon
155
Vaxcyte
PCVX
$9.32B
– –
-1,261,000
Closed -$73.3M
PGEN icon
156
Precigen
PGEN
$2.58B
– –
-50,000
Closed -$194K
PGNY icon
157
Progyny
PGNY
$1.97B
– –
-18,000
Closed -$306K
PIPR icon
158
Piper Sandler
PIPR
$5.3B
– –
-66,000
Closed -$5.05M
PPA icon
159
PUT
Invesco Aerospace & Defense ETF
PPA
$8.25B
– –
-3,600,000
Closed -$691M
QURE icon
160
uniQure
QURE
$3.36B
– –
-14,000
Closed -$229K
ROL icon
161
Rollins
ROL
$17.8B
– –
-93,000
Closed -$4.97M
RPRX icon
162
Royalty Pharma
RPRX
$27.3B
– –
-493,000
Closed -$23.6M
SBRA icon
163
Sabra Healthcare REIT
SBRA
$5.21B
– –
-14,000
Closed -$269K
SCHW
164
Charles Schwab
SCHW
$194B
– –
-3,955,657
Closed -$372M
SDGR icon
165
Schrodinger
SDGR
$1.47B
– –
-17,000
Closed -$193K
SLS icon
166
SELLAS Life Sciences
SLS
$3.12B
– –
-40,000
Closed -$169K
SNDX icon
167
Syndax Pharmaceuticals
SNDX
$1.75B
– –
-10,000
Closed -$234K
SPGI icon
168
S&P Global
SPGI
$127B
– –
-12,000
Closed -$5.1M
SRRK icon
169
Scholar Rock
SRRK
$6.88B
– –
-7,000
Closed -$344K
STOK icon
170
Stoke Therapeutics
STOK
$2.08B
– –
-9,000
Closed -$293K
SUPN icon
171
Supernus Pharmaceuticals
SUPN
$2.67B
– –
-4,000
Closed -$207K
TENB icon
172
Tenable Holdings
TENB
$3.79B
– –
-265,000
Closed -$4.48M
TERN
173
DELISTED
Terns Pharmaceuticals
TERN
– –
-7,000
Closed -$369K
THC icon
174
Tenet Healthcare
THC
$22.6B
– –
-452,153
Closed -$85.3M
TKR icon
175
Timken Company
TKR
$8.67B
– –
-51,000
Closed -$5.13M
4 5 6
7
8

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2026 Portfolio in Review

As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.